Pharmaceutical Granule Homogeneity via Spray Coating and Drying
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing manufacturing process for PICOLAX™, a pharmaceutical product, faces issues with inhomogeneity in final and intermediate products due to low binding properties between citric acid and magnesium oxide, leading to extra processing time, economic losses, and dust production, along with physical degradation of potassium bicarbonate during mixing.
Innovation Solution
A process involving the use of a multi-dimension blender for dry mixing citric acid and magnesium oxide, and spraying a sodium picosulphate solution onto potassium bicarbonate, followed by drying, to create homogeneous granules with a coated layer structure, reducing processing time and improving homogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional mixing processes are used to blend citric acid and magnesium oxide, then the mixing operation can be completed, but inhomogeneity arises in granule size and distribution due to low binding properties between particles
Solution Approach 1:
A binding agent is introduced as an intermediary substance to facilitate adhesion between citric acid and magnesium oxide particles during mixing. This mediator overcomes the low binding properties between the two main ingredients, enabling them to form homogeneous granules with consistent size distribution without excessive dust generation or material loss.
2Reliability
If extra magnesium oxide is added to compensate for losses during blending, then mixing losses are covered, but economic losses increase and processing time extends
Solution Approach 1:
The conventional mechanical mixing system is replaced or supplemented with a granulation process that uses binding agents to create cohesive granules. This substitution prevents material loss during handling and transfer operations, eliminating the need for overage additions and reducing both economic losses and processing time associated with compensating for mixing inefficiencies.
3Ease of manufacture
If conventional mixing is used for potassium bicarbonate and sodium picosulphate, then blending occurs, but physical degradation and dissolution of particles happen during the process
Solution Approach 1:
The ingredients are pre-granulated with binding agents before final mixing, creating robust granule structures that resist physical degradation during subsequent handling and processing. This preliminary granulation action protects particle integrity throughout the manufacturing process, preventing dissolution and smashing that would otherwise occur during conventional blending operations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new process achieves significant reduction in processing time, enhances product homogeneity, minimizes dust and contamination, and ensures uniformity of active substance content, resulting in a more efficient and reproducible final product.
Implementation Method 1
spraying a sodium picosulphate solution onto potassium bicarbonate
Implementation Method 2
drying, to create homogeneous granules with a coated layer structure
Data Source
Figure 1
Figure 2
AI summary
A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavour; products, intermediate products, and uses thereof.